Regional lymph node status in melanoma is an important prognostic factor, where nodal
disease carries a less favorable prognosis than localized disease. The sentinel lymph
node (SLN) is the first regional lymph node draining the tumor and represents the
first site of possible lymphatic metastasis. Sentinel lymph node biopsy (SLNB) for
melanoma can be performed using pre-operative lymphoscintigraphy and intra-operative
gamma-probe detection or visual identification using an injected dye. A commonly used
dye for melanoma in Europe is Patent Blue V (PBV) [Laboratoire Guerbert, Aulnay-Sous-Bois,
France]. Its medical use however carries several potential drawbacks, including allergic
reactions.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Plastic, Reconstructive & Aesthetic SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Anaphylaxis to patent blue dye in a 17-year-old boy.BMJ Case Reports CP. 2019; 12e226191
- NEW START and ALMANAC study groups. Adverse reactions to patent blue V dye - The NEW START and ALMANAC experience.Eur J Surg Oncol. 2010; 36: 399-403
- Incidence of adverse reactions to patent blue dye in melanoma sentinel node biopsy: a major UK centre experience.J Plast Reconstr Aesthet Surg. 2013; 66: 1299-1300
- Sentinel lymph node biopsy in melanoma: the Oxford ten year clinical experience.J. Plast. Reconstr. Aesthet. Surg. 2011; 64: 1284-1290
- A retrospective analysis of rates of allergic reaction to Patent V blue dye used in sentinel lymph node biopsies for melanoma.J Plast Reconstr Aesthet Surg. 2021; 14
Article info
Publication history
Published online: February 04, 2023
Accepted:
January 29,
2023
Received:
October 30,
2022
Identification
Copyright
© 2023 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
